Engineered immune cells take on multiple sclerosis and other nerve diseases
NCT ID NCT07304154
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty immune cells. The study includes people with multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy, and aims to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Concord Repatriation General Hospital
RECRUITINGSydney, New South Wales, 2139, Australia
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
LDS Hospital - Intermountain Health
RECRUITINGSalt Lake City, Utah, 84143, United States
-
Stanford Neuroscience Health Center
RECRUITINGPalo Alto, California, 94304, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KITE-363 (a type of CAR T-cell therapy that targets CD19 and CD20 proteins on immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat autoimmune neurologic diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
What could go wrong
This is an early Phase 1 trial with only 52 participants, so safety and effectiveness are not yet proven. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and nervous system problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.